0000899243-21-026769.txt : 20210630 0000899243-21-026769.hdr.sgml : 20210630 20210630170514 ACCESSION NUMBER: 0000899243-21-026769 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210628 FILED AS OF DATE: 20210630 DATE AS OF CHANGE: 20210630 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bolzon Bradley J PhD CENTRAL INDEX KEY: 0001354345 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 211062690 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-28 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001354345 Bolzon Bradley J PhD MONTE ROSA THERAPEUTICS, INC. 645 SUMMER STREET, SUITE 102 BOSTON MA 02210 1 0 1 0 Common Stock 2021-06-28 4 C 0 6515869 A 6799115 I By Versant Venture Capital VI, L.P. Common Stock 2021-06-28 4 C 0 1940043 A 1940043 I By Versant Vantage I, L.P. Common Stock 2021-06-28 4 P 0 157895 19.00 A 2097938 I By Versant Vantage I, L.P. Series A convertible preferred stock 2021-06-28 4 C 0 20004280 D Common Stock 5666131 0 I By Versant Capital VI, L.P. Series B convertible preferred stock 2021-06-28 4 C 0 3000000 D Common Stock 849738 0 I By Versant Capital VI, L.P. Series B convertible preferred stock 2021-06-28 4 C 0 4150000 D Common Stock 1175470 0 I By Versant Vantage I, L.P. Series C convertible preferred stock 2021-06-28 4 C 0 2699328 D Common Stock 764573 0 I By Versant Vantage I, L.P. Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. /s/ Ajim Tamboli, Attorney-in-Fact 2021-06-30